bioAffinity shareholders approve reverse stock split, share increase, and anti-dilution warrant adjustments

bioAffinity Technologies, Inc.

All seven proposals passed at July 25, 2025 Annual Meeting.
Reverse stock split approved; no adjournment needed as all measures passed.
Share increase amendment approved, allowing more authorized shares.
Issuance of up to 2.93M shares upon warrant exercise approved.
Anti-dilution provision approved, allowing up to 49.9M additional shares upon warrant exercise.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.